open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22
Get Citation

Do we know everything about anthracyclines in the adjuvant treatment of breast cancer?

Renata Sienkiewicz-Kozłowska, Iwona Głogowska, Dominika Jaxa-Larecka, Tadeusz Pieńkowski

open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

Abstract

Systemic adjuvant treatment has established role in the treatment of breast cancer and anthracyclinecontaining regimens has been commonly used for over 20 years. The efficacy of these regimens has been proved in many clinical trials and meta-analyses, regardless of risk factors, age and hormonal status of patients. In search of more effective methods of treatment combination of anthracyclines and taxanes was tested and recently in the group of patients with HER2 overexpression trastuzumab was introduced to treatment. The main problem related to adjuvant treatment with anthracyclines is cardiotoxicity and that is the basis of searching new regimens and methods of treatment which would allow to eliminate or limit the use of anthracyclines in the adjuvant treatment of breast cancer
Onkol. Prak. Klin. 2010; supl. A: A1–A7

Abstract

Systemic adjuvant treatment has established role in the treatment of breast cancer and anthracyclinecontaining regimens has been commonly used for over 20 years. The efficacy of these regimens has been proved in many clinical trials and meta-analyses, regardless of risk factors, age and hormonal status of patients. In search of more effective methods of treatment combination of anthracyclines and taxanes was tested and recently in the group of patients with HER2 overexpression trastuzumab was introduced to treatment. The main problem related to adjuvant treatment with anthracyclines is cardiotoxicity and that is the basis of searching new regimens and methods of treatment which would allow to eliminate or limit the use of anthracyclines in the adjuvant treatment of breast cancer
Onkol. Prak. Klin. 2010; supl. A: A1–A7
Get Citation

Keywords

breast cancer; adjuvant treatment; anthracyclines

About this article
Title

Do we know everything about anthracyclines in the adjuvant treatment of breast cancer?

Journal

Oncology in Clinical Practice

Issue

Vol 6, Supp. A (2010)

Pages

1-7

Published online

2010-11-22

Keywords

breast cancer
adjuvant treatment
anthracyclines

Authors

Renata Sienkiewicz-Kozłowska
Iwona Głogowska
Dominika Jaxa-Larecka
Tadeusz Pieńkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl